4qc0
From Proteopedia
(Difference between revisions)
Line 1: | Line 1: | ||
==Crystal structure of human TLR8 in complex with XG-1-236== | ==Crystal structure of human TLR8 in complex with XG-1-236== | ||
- | <StructureSection load='4qc0' size='340' side='right' caption='[[4qc0]], [[Resolution|resolution]] 2.10Å' scene=''> | + | <StructureSection load='4qc0' size='340' side='right'caption='[[4qc0]], [[Resolution|resolution]] 2.10Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[4qc0]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QC0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QC0 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4qc0]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QC0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QC0 FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=XG1:2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE'>XG1 | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=XG1:2-BUTYL-2H-PYRAZOLO[3,4-C]QUINOLIN-4-AMINE'>XG1</scene></td></tr> |
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4qbz|4qbz]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4qbz|4qbz]]</td></tr> | ||
+ | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">TLR8 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qc0 OCA], [http://pdbe.org/4qc0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qc0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qc0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qc0 ProSAT]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qc0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qc0 OCA], [http://pdbe.org/4qc0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4qc0 RCSB], [http://www.ebi.ac.uk/pdbsum/4qc0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4qc0 ProSAT]</span></td></tr> | ||
</table> | </table> | ||
Line 19: | Line 20: | ||
</div> | </div> | ||
<div class="pdbe-citations 4qc0" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 4qc0" style="background-color:#fffaf0;"></div> | ||
+ | |||
+ | ==See Also== | ||
+ | *[[Toll-like Receptors|Toll-like Receptors]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
+ | [[Category: Human]] | ||
+ | [[Category: Large Structures]] | ||
[[Category: Ohto, U]] | [[Category: Ohto, U]] | ||
[[Category: Shimizu, T]] | [[Category: Shimizu, T]] |
Revision as of 09:33, 24 April 2019
Crystal structure of human TLR8 in complex with XG-1-236
|
Categories: Human | Large Structures | Ohto, U | Shimizu, T | Tanji, H | Antiviral and antitumor drug binding | Glycosylation | Innate immunity | Leucine rich repeat | Rna binding protein | Rna receptor | Rna recognition | Ssrna | Structure-based ligand design | Tlr8 and tlr7 agonist | Vaccine adjuvant